Form 8-K

8-K — IOVANCE BIOTHERAPEUTICS, INC.

Accession: 0001104659-26-111583

Filed: 2026-09-29

Period: 2026-09-29

CIK: 0001425205

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2626507d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2626507d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2626507d1_8k.htm · Sequence: 1

false

0001425205

2026-09-29

0001425205

dei:FormerAddressMember

2026-09-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 29, 2026

IOVANCE BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its

Charter)

Delaware

001-36860

75-3254381

(State

or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

300

Rouse Blvd.

Philadelphia,

Pennsylvania

19112

(Address

of Principal Executive Offices)

(Zip

Code)

Registrant’s

Telephone Number, Including Area Code: 650 260-7120

825

Industrial Road, Suite 100

San

Carlos, California 94070

(Former Name or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨   Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title

of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common

Stock, par value $0.000041666

IOVA

The

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate

by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial

accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press

release updating its full year 2026 revenue guidance. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein

by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release of Iovance Biotherapeutics, Inc., dated

September 29, 2026

104

Cover Page Interactive Data File (embedded as Inline

XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Iovance

Biotherapeutics, Inc.

Date:

September 29, 2026

By:

/s/

Frederick G. Vogt

Name:

Frederick G. Vogt, Ph.D., J.D.

Title:

Interim CEO and President, and General Counsel

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2626507d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Iovance Biotherapeutics

Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

New Guidance

Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million

Strong U.S. Demand

for Amtagvi and Proleukin Drives Increased Outlook

PHILADELPHIA, Pennsylvania, September 29,

2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing,

and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026

total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin. The midpoint

represents an increase of $55 million, or ~15%, over the previous guidance range of $350 to $370 million and implies nearly 60% annual

growth in total revenue.

“Our record second quarter and

sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint,”

said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. “Increasing patient demand and our current

manufacturing schedule provide strong visibility into our third and fourth quarter revenues. In addition, lifileucel continues to advance

across our registrational programs in new solid tumor indications, while continued manufacturing and operating efficiencies accelerate

our progress toward profitability.”

Iovance most recently reported record

second quarter 2026 total product revenue of $99.3 million, has grown its authorized treatment center (ATC) network to ~100 centers,

and remains on track for expansion to at least 110 ATCs by year-end 2026.

Iovance expects to report third quarter

2026 financial results in early November 2026. This update completes the guidance review announced with the Company’s second

quarter 2026 results.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is

the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid

tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved

in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans

registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies,

next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly

accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based

manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and

laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in

many countries around the world. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design

marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks

of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property

of their respective owners.

Information on Iovance’s broad,

industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters

discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred

to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities

Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,”

“believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,”

“plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,”

“can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty

of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions

and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future

developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date

of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future

events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and

other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements,

and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors

that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described

in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most

recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial

known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our

products; the acceptance by the market of our products and product candidates, if approved, and their potential pricing and/or reimbursement

by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product

candidates; the risk regarding our ability to manufacture our therapies at our iCTC facility, including the risk that our ability

to increase manufacturing capacity at our facility may adversely affect our commercial launch; the risks related to our ability to obtain,

maintain and enforce patent and other intellectual property protection for our products and product candidates; the risk that the successful

development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable

in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain

regulatory authority approval of our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings

with regulatory authorities, may support registrational studies and subsequent approvals by regulatory authorities, including the risk

that any of our planned registrational trials may not support approval; preliminary and interim clinical results, which may include efficacy

and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials

or subgroups within these trials or in other prior trials or cohorts; the risk that we may be required to conduct additional clinical

trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of

the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or

communications by such regulatory authorities; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue

or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that

unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk

that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number

of ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance,

including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and

other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided

in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor

coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period

covered by this press release; and no material fluctuation in exchange rates.

CONTACTS

Investors

IR@iovance.com

650-260-7120 ext. 150

Media

PR@iovance.com

650-260-7120 ext. 150

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Sep. 29, 2026

Entity Addresses [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 29, 2026

Entity File Number

001-36860

Entity Registrant Name

IOVANCE BIOTHERAPEUTICS, INC.

Entity Central Index Key

0001425205

Entity Tax Identification Number

75-3254381

Entity Incorporation, State or Country Code

Entity Address, Address Line One

300

Rouse Blvd.

Entity Address, City or Town

Philadelphia

Entity Address, State or Province

Entity Address, Postal Zip Code

19112

City Area Code

650

Local Phone Number

260-7120

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.000041666

Trading Symbol

IOVA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Former Address [Member]

Entity Addresses [Line Items]

Entity Address, Address Line One

825

Industrial Road

Entity Address, Address Line Two

Suite 100

Entity Address, City or Town

San

Carlos

Entity Address, State or Province

Entity Address, Postal Zip Code

94070

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressesLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: